Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

PROSTATE CANCER THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Millions. Analytics in the report specifically focuses on revenues generated from hormonal therapies.The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 138 companies including many key and niche players worldwide such as Abbott Laboratories, Æterna Zentaris Inc., ALZA Corporation, Amgen Inc., AstraZeneca PLC., Medimmune, LLC, Bristol-Myers Squibb Company, Cell Genesys Inc., Dendreon Corporation, EUSA Pharma, (USA) Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc., Immunomedics, Inc., Indevus Pharmaceuticals Inc., Novartis AG, OSI Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc., Progenics Pharmaceuticals, Inc., Sanofi-Aventis SA, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1747
Price : $3950
Companies : 138
Pages : 739
Date : April 2009
Market Data Tables : 337

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  PROSTATE CANCER THERAPEUTICS (Complete Report) Pages : 739   | $3950
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3
Hormonal Therapy.....I-3
  
   Radiation Therapy.....I-4
Chemotherapy.....I-4
Surgical Procedures.....I-4
Other Treatment Options.....I-4
  
II. EXECUTIVE SUMMARY101$2250
  1. Industry Overview.....II-113 $1450  
   A Prelude .....II-1
New Products to Bolster Sales of Prostate Cancer Therapeutics.....II-1
1$100
   Key Prostate Cancer Drugs & Companies.....II-2
Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market.....II-2
Table 1: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US for 2007 (includes corresponding Graph/Chart).....II-2
1$350
   Select Prostate Cancer Hormonal Therapy Drugs with Year of FDA Approval.....II-3
Targeted Therapy - The New Frontier of Cancer Treatment.....II-3
Radiotherapy - Gaining Prominence.....II-3
1$100
   Innovations in Drug Delivery: A Key Factor in Product Differentiation.....II-4
New Therapies Appear Over the Horizon.....II-4
New Generation Prostate Cancer Drugs and Their Area of Use.....II-4
1$100
   Small Cap Companies: A Target of Private Capital Financing.....II-5
Drugs (that are both available and under pipeline) Developed by the Three Small-Cap
  Companies.....II-5
Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets.....II-5
1$100
   Awareness Drives European Prostate Cancer Therapeutics Market.....II-6
Growth Drivers.....II-6
Rise in Prostate Cancer Incidences & Access to Modern Therapeutics Foster
  Growth.....II-6
Table 2: New Incidences of Prostate Cancer (in ‘000) Worldwide for the years 2004 through 2007 (includes corresponding Graph/Chart).....II-6
1$350
   Table 3: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart).....II-7
Demographics & Lifestyles Raise the Risk of Prostate Cancer.....II-7
Table 4: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding Graph/Chart).....II-7
1$350
   Table 5: Male Population by Age Group in the US for the year 2007 (includes corresponding Graph/Chart).....II-8
Select General Risk Factors and their Relative Risk Rate in Prostate Cancer.....II-8
Unmet Needs Leave Scope for Further Research and Development.....II-8
Supportive Cancer Drugs Contribute to Growth.....II-8
1$350
   Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate
  Cancer.....II-9
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth.....II-9
Table 6: Five-Year Prostate Cancer Survival Rate in the US by Race, 1975-2002 (includes corresponding Graph/Chart).....II-9
1$350
   Table 7: Five-Year Cancer Survival Rate Among US Males by Type – Prostate and Testis (1996-2002) (includes corresponding Graph/Chart).....II-10

Table 8: Five-Year Cancer Survival Rate (%) in the US by Race, 1996-2003 (includes corresponding Graph/Chart).....II-10
1$350
   Molecular Imaging of Cancer: Critical in Improving Patient Outcomes.....II-11
Growth Restraints.....II-11
Limited Tumor Specificity and Toxicity.....II-11
Complicated Treatment Protocols: A Major Stumbling Block in Patient
  Compliance.....II-11
1$100
   Multiple Drug Resistance.....II-12
Stringent Regulations Delay Market Approval.....II-12
Ongoing Clinical Trials in Hormone Refractory Prostate Cancer.....II-12
Challenges Encountered in Clinical Trials.....II-12
1$100
   Notable Prostate Cancer Drug Failures in Phase III Development.....II-13
High Development Costs Retracts Manufacturers in Developing Countries.....II-13
1$100
  2. Clinical Trials.....II-143 $300  
   Drugs in Pipeline.....II-14
Select Prostate Cancer Drugs/Compounds in Pipeline.....II-14
1$100
   Select Prostate Cancer Drugs Under Phase II/III Trials by Leading Companies.....II-151$100
   Drugs in Pre-Clinical Stage.....II-16
Select Prostate Cancer Drugs/Compounds in Pre-Clinical Stage.....II-16
Commercially Available Drugs.....II-16
Select Prostate Cancer Drugs (Commercially Available) by Leading Companies.....II-16
1$100
  3. Product Overview.....II-1715 $1650  
   Cancer: A Major Health Crises in the Modern World.....II-17
Table 9: Mortality Rate in the US for the Year 2005 by Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory Diseases, and Accidents (Unintentional Injuries) (includes corresponding Graph/Chart).....II-17

Table 10: Mortality Rate in the US for the Year 2005: Percentage Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular diseases, Chronic lower respiratory diseases, Accidents (unintentional injuries), and Others (includes corresponding Graph/Chart).....II-17
1$350
   Table 11: Cancer Death Rates in the US (2007): Percentage Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas, Leukemia, and Others (includes corresponding Graph/Chart).....II-18

Table 12: Comparison of Mortality Among African Americans and Whites by Cancer Type in the US, 2000- 2004 (includes corresponding Graph/Chart).....II-18
Prostate - Structure.....II-18
1$350
   Pituitary Gland.....II-19
Testes.....II-19
1$100
   Prostate Cancer - A Primer.....II-20
Key Facts to Gaze at.....II-20
Table 13: Lifetime Probability of Developing Cancer (in Men) by Type in the US, 2002-2004.....II-20
1$350
   Table 14: New Incidences of Prostate Cancer (in ‘000) Worldwide for the years 2007 and 2008 (includes corresponding Graph/Chart).....II-211$350
   Table 15: Mortality Due to Prostate Cancer (in ‘000) Worldwide for the Years 2007 and 2008 (includes corresponding Graph/Chart).....II-221$350
   Table 16: Male Population (in Million) for the Year 2007 for Select Regions (includes corresponding Graph/Chart).....II-231$350
   Screening/Detection of Prostate Cancer.....II-24
Digital Rectal Exam (DRE).....II-24
Transrectal Ultrasound (TRUS).....II-24
PSA Blood Test.....II-24
Strategies to Enhance Screening/Detection of Prostate Cancer.....II-24
1$100
   Improved PSA Testing.....II-25
Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels.....II-25
Insulin-like Growth Factor (IGF-1) and Intact IGF- Binding Protien-3
  (IGF-BP3).....II-25
GSTP1 Methylation Levels and Prostate Cancer Diagnosis.....II-25
1$100
   Microbubble Ultrasound.....II-26
Staging of Prostate Cancer.....II-26
1$100
   Gleason Score.....II-27
Gleason Score and Grading of Prostate Cancer.....II-27
TNM Staging.....II-27
T-Staging Analysis of Prostate Cancer.....II-27
1$100
   Genetic & Non-Genetic Factors.....II-28
Hereditary or Genetic Factors.....II-28
Non-Genetic or Environmental Factors.....II-28
1$100
   Table 17: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart).....II-291$350
   Prevention of Cancer.....II-30
Role of Diet in Prostate Cancer.....II-30
2$200
  4. Treatment Options for Prostate Cancer.....II-3221 $1300  
   Hormonal Therapy.....II-32
Medical Hormone Therapy.....II-32
1$100
   LHRH Analogs.....II-33
Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment.....II-33
1$100
   Anti-Androgens.....II-34
Leading Non-Steroidal Anti-androgen Hormonal Therapy Drugs for Prostate
  Cancer.....II-34
Anti-Androgen Monotherapy.....II-34
1$100
   Orchiectomy.....II-35
Side Effects of Orchiectomy.....II-35
Time to Start Hormonal Therapy.....II-35
1$100
   Strategies to Enhance Hormonal Treatment.....II-36
Combination Therapy.....II-36
Intermittent Therapy.....II-36
Radiation Therapy.....II-36
Brachytherapy.....II-36
1$100
   Treatment Procedure.....II-371$100
   Benefits of Brachytherapy.....II-38
Drawbacks of Brachytherapy.....II-38
1$100
   High Dose Rate (HDR) Brachytherapy.....II-39
External Beam Radiation Therapy (EBRT).....II-39
Side Effects of Radiotherapy.....II-39
Strategies to Enhance Radiation Treatment.....II-39
New Radiation Techniques.....II-39
1$100
   Whole Pelvic Radiation Therapy (WPRT).....II-40
New Radiation Devices.....II-40
Chemotherapy.....II-40
1$100
   Risks Associated with Chemotherapy.....II-41
Surgical Procedures for Prostate Cancer.....II-41
Transurethral Resection of the Prostate (TURP).....II-41
1$100
   Prostatectomy and Lymph Node Dissection.....II-42
Radical Prostatectomy.....II-42
1$100
   Cryosurgery.....II-43
Advantages of Cryosurgery.....II-43
Disadvantages of Cryosurgery.....II-43
Other Treatment Options.....II-43
Intensity Modulated Radiation Therapy (IMRT).....II-43
1$100
   Benefits of IMRT.....II-44
Drawbacks of IMRT.....II-44
Androgen Deprivation Therapy (ADT).....II-44
1$100
   High Dose Radiation (HDR) Monotherapy.....II-45
Drawbacks of HRD.....II-45
Choosing the Optimal Treatment Method .....II-45
1$100
   Recurrent Prostate Cancer.....II-46
Recurrent Prostate Cancer Subsequent to Surgery.....II-46
1$100
   Recurrent Prostate Cancer Subsequent to Radiation Therapy.....II-47
Hormone-Refractory Prostate Cancer (HRPC).....II-47
Select Drugs in Advanced Development Stage for Hormone-Refractory Prostate
  Cancer.....II-47
Chemotherapy.....II-47
1$100
   TCaxotere® (Docetaxel).....II-48
Bone Complication Treatments.....II-48
Bisphosphonate Drugs.....II-48
1$100
   Doxazosin, a Cytotoxic Drug for Prostate Cancer.....II-49
Radiation Therapy.....II-49
Strategies to Enhance Recurrent Prostate Cancer Treatment.....II-49
Chemotherapy - New Regimens.....II-49
1$100
   Phase I Clinical Trials.....II-50
Combination Therapy.....II-50
Gene Therapy.....II-50
Targeted Therapy.....II-50
1$100
   Selective Endothelia A Receptor Antagonist - (SERA™).....II-511$100
   Other Select Targeted Therapies.....II-52
Tyrosine Kinase Inhibitors.....II-52
Anti-Angiogenic Drugs.....II-52
Monoclonal Antibodies.....II-52
Vaccines.....II-52
Radioactive Monoclonal Antibodies.....II-52
1$100
  5. Drug Approvals and Clinical Studies.....II-5313 $800  
   Debiopharm Unveils Results of Phase III Study of Trelstar in Prostate Cancer
  Treatment.....II-53
Algeta to Start Clinical Study of Alpharadin in HRPC.....II-53
Ferring Receives FDA Approval for Degarelix in Prostate Cancer.....II-53
Isis and OncoGenex Reveals Positive results of OGX- 011 Molecule in HRPC.....II-53
Antisoma Completes Phase 2 Study of ASA404 in Prostate Cancer.....II-53
1$100
   Cougar Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate
  Cancer.....II-54
Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate
  Cancer.....II-54
Peregrine Pharmaceuticals Reveals Pre-Clinical Data on Bavituximab in Prostate
  Cancer.....II-54
Cell Genesys Reveals Data of GVAX Immunotherapy for Treatment of Prostate
  Cancer.....II-54
1$100
   Bioponic Phytoceuticals Unveils Pre-Clinical Data on Curecumin™ for Prostate
  Cancer.....II-55
New Study Reveals Cough Medicine – Noscapine to be Effective in Prostate
  Cancer.....II-55
Fosamax® Found Effective in Preventing Bone Loss in Prostate Cancer Patients.....II-55
Genta Unveils Results of Phase II Clinical Trial of Genasense® in Prostate
  Cancer.....II-55
1$100
   Cell Therapeutics Reveals Phase 2 Clinical Trial Results of XYOTAX™ in Androgen
  Independent Prostate Cancer Patients.....II-56
Sanofi-Aventis’ Taxotere® Enhances Survival in Metastatic Prostate Cancer
  Patients.....II-56
NCI Initiates Phase 2 Clinical Trial of Cytogen’s QUADRAMET for HRPC.....II-56
1$100
   Cleveland BioLabs to Initiate Phase II Clinical Trial for Curaxin in HRPC.....II-57
NeoRx Begins Clinical Study for Picoplatin in Prostate Cancer.....II-57
Novacea Starts Phase III Clinical Trial for Treatment of Prostate Cancer.....II-57
Next Pharmaceuticals’ Supplement Nexrutine Help Prevent Prostate Cancer.....II-57
Antisoma Reveals Results from AS1404 Phase II Clinical Trial in HRPC.....II-57
1$100
   Marshall Edwards Conducts Study on Phenoxodiol in Prostate Cancer.....II-58
Combination of Provenge® and Taxotere® Offer Better Results for HRPC Patients.....II-58
Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy.....II-58
1$100
   University of California’s Analyses Support Dendreon’s Active Cellular
  Immunotherapy.....II-59
Spectrum Announces Positive Outcome of Satraplatin Trial on HRPC Patients.....II-59
1$100
   Panacea Pharmaceuticals Identifies Blood Protein for Early Prostate Cancer
  Detection.....II-60
1$100
   Active Biotech Reveals Results of TASQ Phase I Study for Prostate Cancer.....II-61
Positive Results of Combined Hormone and Radiation Therapies in Locally Advanced
  Prostate Cancer.....II-61
Positive Results from Use of IMRT in Localized Prostate Cancer.....II-61
1$100
   Balanced Intake of Omega-6 and Omega-3 Fatty Acids Found to Reduce Prostate Cancer
  Growth.....II-62
Sanofi’s Taxotere Gains Approval from Nice of UK for Use in Late-Stage Prostate
  Cancer.....II-62
1$100
   Protox Gains Clearance from FDA to Conduct Phase I Trial of PRX302.....II-63
Æterna Zentaris’s Ozarelix Phase II Trial Shows Positive Results.....II-63
1$100
   Biomira Announces Results of Stimuvax Phase 2 Clinical Study.....II-64
Cytogen Receives FDA Clearance for CYT-500 IND Application.....II-64
US Researchers Unveils New Therapeutic Cancer Vaccine For Metastatic Prostate
  Cancer.....II-64
1$100
   PNNL and IsoRay Develops Cesium-131 Seed for Treatment of Prostate Cancer.....II-65
1$100
  6. Product Innovations/Introductions.....II-662 $200  
   Speciality European Pharma Introduces Plenaxis.....II-66
Actavis Unveils Bicalutamide Tablets for Prostate Cancer in the European
  Markets.....II-66
Artemis to Introduce IGRT.....II-66
Immunomedics Introduces Immunotoxin for Treatment of Prostate and Lung Cancer.....II-66
1$100
   Barr Unveils Generic Version of Proscar® Tablets.....II-67
IRX Therapeutics to Develop Vaccine for Prostate Cancer.....II-67
Actavis Introduces New Generic Drugs in Europe.....II-67
Robot-Assisted Radical Prostatectomy for Treatment of Prostate Cancer.....II-67
1$100
  7. Recent Industry Activity.....II-6822 $1200  
   Sanofi-Aventis Secures Approval of Japanese Health Ministry for Taxotere®
  Injection.....II-68
Schering-Plough Terminates Collaboration with Novacea.....II-68
Takeda Terminates JV Deal, Merges its Subsidiaries.....II-68
Aureon Laboratories and Pfizer Announce Research Partnership.....II-68
1$100
   Celera Enters into Licensing Agreement with Merck.....II-69
Celera Announces Demerger from Applera Corporation.....II-69
1$100
   GPC Biotech and Celgene Terminate Agreement for Satraplatin.....II-70
EUSA Acquires Cytogen Corporation.....II-70
Eisai Acquires MGI Pharma.....II-70
BN ImmunoTherapeutics Enters into a Scientific Partnership with NCI.....II-70
1$100
   Morphotek® Enters into Licensing Agreement with NCI.....II-71
ValiRx Acquires Exclusive Evaluation License from CRT for New Prostate Cancer
  Compound.....II-71
Cell Genesys Forms Global Alliance with Takeda on GVAX Immunotherapy Development for
  Prostate Cancer.....II-71
1$100
   Sirnaomics Extends Partnership with GRL to Develop Multi-Targeted RNAi Therapeutic
  Products.....II-72
Aureon and Pfizer to Collaborate on New Stage of Research Project.....II-72
CancerPartners UK Collaborates with Spire Healthcare.....II-72
1$100
   Cougar Biotech Enters into an Agreement with US FDA.....II-73
Scottish Scientists Receives Contract from Cancer Research UK.....II-73
ValiRx Collaborates with University of Surrey on Prostate Cancer Diagnostics.....II-73
ValiRx Subsidiary Extends Collaboration with Cancer Research Technology.....II-73
1$100
   MacroArray Partners with Abbott on PCADM-1 Test for Prostate Cancer.....II-74
Novacea Enters into Agreement with Schering-Plough.....II-74
Bayer to Stop Sale of Viadur – A Drug for Prostate Cancer.....II-74
1$100
   Sagemark Embarks on Radiation Therapy Venture.....II-75
RTS Concludes Californian Radiation Therapy Center Acquisition.....II-75
Radiation Therapy Takes Over a North Carolina Treatment Center.....II-75
DRAXIMAGE and Med Discovery Enter into Research Collaboration.....II-75
1$100
   Core Oncology Completes Acquisition of Coloplast’s Brachytherapy Business.....II-76
Novacea Licenses Asenstar Prostate Cancer Drug to Schering-Plough.....II-76
Bentley Receives Approval for Generic Version of Casodex.....II-76
1$100
   GSK Acquires Praecis Pharmaceuticals.....II-77
Samaritan Acquires Metastatin Pharma.....II-77
Champions Biotechnology Acquires Patent Rights for Potential Cancer Treatments.....II-77
GPC Biotech Submits NDA for Treatment of Prostate Cancer.....II-77
1$100
   MedMira Inks Agreement to Take Over Rights of a New Marker Technology.....II-78
Cell Genesys’s GVAX Prostate Cancer-Treatment Attains FDA’s Fast Track Tag.....II-78
Envisioneering Medical Enters into Agreement with BrachySciences.....II-78
1$100
   Signet Enters into Agreement with AsymmetRx to Distribute ‘Prostate-63’ Tests.....II-79
Mylan Pharmaceuticals Obtains FDA Approval for Finasteride’s ANDA.....II-79
Æterna Zentaris Enters into Agreement with Nippon Kayaku.....II-79
1$100
   Progenics Pharmaceuticals Broadens Association with Seattle Genetics.....II-80
Diosynth and Dendreon Sign Multi-Year Commercial Supply Deal.....II-80
Genstar Capital Completes Acquisition of OnCure.....II-80
Generex Biotechnology Expands Antigen Express Cancer Trials.....II-80
1$100
   Progenics Pharmaceuticals Acquires PSMA Development Company.....II-81
Schweizerhall Acquires Novosis.....II-81
Misonix Expands into France with Sonablate® 500.....II-81
1$100
   Indevus Enters into Agreement to Takeover Valera.....II-82
Oncobionic Receives FDA Clearance for Cancer Treatment Technology.....II-82
Misonix Expands HIFU Business in Europe by Entering into Spain.....II-82
1$100
   Altana Divests Entire Stake in GPC Biotech.....II-83
Ipsen Enters into Partnership with GTx to Develop and Market Acapodene in
  Europe.....II-83
Egenix and Proteome Systems Collaborate to Develop Prostate Cancer Test Using
  Semen.....II-83
1$100
   Valera and Spepharm Partner to Market Vantas, and Supprelin-LA.....II-84
SurModics and AbbeyMoor Collaborate to Develop Products to Treat Prostate
  Diseases.....II-84
Dendreon Constructs Manufacturing Facility in New Jersey.....II-84
1$100
   MediGene Introduces Prostate Cancer Drug in Italian Market.....II-85
Gen-Probe Introduces Innovative Test for Prostate Cancer in Europe.....II-85
DRL Introduces Generic Version of Proscar.....II-85
Ferring Partners with Astellas on Degarelix License for Prostate Cancer
  Treatment.....II-85
1$100
   Protox Acquires PRX321 Cancer Program from US Public Health Service and
  Neurocrine.....II-86
Astex Collaborates with CRT and Newcastle University for New Drug Discovery.....II-86
Miraculins and Duke University Enter into Collaboration.....II-86
Bayer Receives Rights to Prostate Cancer and Transplantation Drug Test from
  Abbott.....II-86
Encorium Group Signs Contract with Global Biopharmaceutical Company.....II-86
1$100
   Paladin Signs an Agreement with Watson for Supply and Sale of Trelstar®.....II-87
BioWa Obtains License for Anti-FGF8 Antibody from Kyowa Hakko.....II-87
OncoGenex and Isis Pharmaceuticals Expand Partnership.....II-87
1$100
   Caprion and AstraZ eneca Enter into Collaboration.....II-88
Innovate Oncology and Prostagenics Enter into Capridine- Beta Development
  Agreement.....II-88
Protein Design Labs Sublicenses Antibody-Drug Conjugates Development Rights to
  Genentech.....II-88
1$100
   National Cancer Institute Enters into Agreement with Illumina.....II-89
Sosei Seeks Marketing Rights for Prostate Cancer Drug in Japan.....II-89
1$100
  8. Focus on Select Global Players.....II-9010 $700  
   Abbott Laboratories (USA).....II-90
Æterna Zentaris Inc......II-90
ALZA Corporation (USA).....II-90
1$100
   Amgen Inc. (USA).....II-91
AstraZeneca PLC (UK).....II-91
1$100
   Medimmune, LLC (USA).....II-92
Bristol-Myers Squibb Company (USA).....II-92
Cell Genesys Inc. (USA).....II-92
1$100
   Dendreon Corporation (USA).....II-93
EUSA Pharma, (USA) Inc. (USA).....II-93
1$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-94
Genentech Inc. (USA).....II-94
1$100
   GlaxoSmithKline Plc (UK).....II-95
Immunomedics, Inc. (USA).....II-95
Indevus Pharmaceuticals Inc. (USA).....II-95
1$100
   Novartis AG (Switzerland).....II-96
OSI Pharmaceuticals, Inc. (USA).....II-96
1$100
   Paladin Labs Inc. (Canada).....II-97
Pfizer Inc. (USA).....II-97
Progenics Pharmaceuticals, Inc. (USA).....II-97
1$100
   Sanofi-Aventis SA (France).....II-98
Spectrum Pharmaceuticals, Inc. (USA).....II-98
Takeda Pharmaceutical Company Limited (Japan).....II-98
2$200
  9. Global Market Perspective.....II-100   
   Table 18: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/ Country – US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1001$350
   Table 19: World 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1011$350
III. MARKET79$1950
  1. The United States.....III-141 $1675  
   A. Market Analysis.....III-1
Overview.....III-1
A Surging US Prostate Cancer Therapeutics Market.....III-1
Table 20: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding Graph/Chart).....III-1
1$200
   Table 21: Male Population by Age Group in the US for the Year 2007 (includes corresponding Graph/Chart).....III-2
Cost of Cancer Drugs – A Major Concern in the US.....III-2
Market Accelerators.....III-2
1$200
   Market Challenges.....III-3
Market Inhibitors.....III-3
Table 22: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US for 2007 (includes corresponding Graph/Chart).....III-3
Current and Future Analysis.....III-3
1$200
   Key Statistics.....III-4
Table 23: Mortality Rate in the US for the Year 2005 by Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory Diseases, and Accidents (Unintentional Injuries) (includes corresponding Graph/Chart).....III-4

Table 24: Mortality Rate in the US for the Year 2005: Percentage Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular diseases, Chronic lower respiratory diseases, Accidents (unintentional injuries), and Others (includes corresponding Graph/Chart).....III-4

Table 25: Cancer Death Rates in the US (2007): Percentage Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas, Leukemia, and Others (includes corresponding Graph/Chart).....III-4
1$200
   Table 26: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart).....III-5

Table 27: New Cases of Prostate Cancer Diagnosed in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart).....III-5
1$200
   Table 28: Mortality Due to Prostate Cancer in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart).....III-6

Table 29: Lifetime Probability of Developing Cancer (in Men) by Type in the US, 2002-2004.....III-6
1$200
   Table 30: Comparison of Mortality Among African Americans and Whites by Cancer Type in the US, 2000-2004 (includes corresponding Graph/Chart).....III-7

Table 31: Five-Year Prostate Cancer Survival Rate in the US by Race, 1975-2002 (includes corresponding Graph/Chart).....III-7
1$200
   Table 32: Five-Year Cancer Survival Rate Among US Males by Type – Prostate and Testis (1996-2002) (includes corresponding Graph/Chart).....III-8

Table 33: Five-Year Cancer Survival Rate (%) in the US by Race, 1996-2003 (includes corresponding Graph/Chart).....III-8
1$200
   Table 34: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart).....III-9
Clinical Trials.....III-9
10$575
   Product Launches.....III-19
Strategic Corporate Developments.....III-19
13$675
   Select Players.....III-329$675
   B. Market Analytics.....III-41
Table 35: US Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-41
1$200
  2. Europe.....III-426 $650  
   A. Market Analysis.....III-42
Overview.....III-42
Awareness Drives European Prostate Cancer Therapeutics Market.....III-42
Table 36: New Cases of Prostate Cancer Diagnosed in Europe: Breakdown by Region/Country for the Years 2007 and 2008 (In ‘000) (includes corresponding Graph/Chart).....III-42
1$200
   Table 37: Mortality Due to Prostate Cancer in Europe: Breakdown by Region/ Country for the Years 2007 and 2008 (In ‘000) (includes corresponding Graph/Chart).....III-43
Current and Future Analysis.....III-43
Clinical Trial.....III-43
1$200
   Product Launches.....III-44
Strategic Corporate Developments.....III-44
2$150
   B. Market Analytics.....III-46
Table 38: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country – France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-46
1$200
   Table 39: European 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country – Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-47
1$200
  2a. France.....III-484 $300  
   A. Market Analysis.....III-48
Overview.....III-48
Anti-Androgen and LHRH Analogs Drive the French Market.....III-48
Current and Future Analysis.....III-48
Clinical Trials.....III-48
1$75
   Strategic Corporate Developments.....III-491$75
   Select Players.....III-501$75
   B. Market Analytics.....III-51
Table 40: French Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-51
1$200
  2b. Germany.....III-523 $225  
   A. Market Analysis.....III-52
Current and Future Analysis.....III-52
Product Launch.....III-52
Strategic Corporate Developments.....III-52
2$150
   GPC Biotech AG – A Major Player.....III-54
B. Market Analytics.....III-54
Table 41: German Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-54
1$200
  2c. Italy.....III-552 $200  
   A. Market Analysis.....III-55
Italian Prostate Cancer Therapeutics Market – An Overview.....III-55
Current and Future Analysis.....III-55
Clinical Trial.....III-55
Strategic Corporate Development.....III-55
1$75
   B. Market Analytics.....III-56
Table 42: Italian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-56
1$200
  2d. The United Kingdom.....III-576 $350  
   A. Market Analysis.....III-57
Overview.....III-57
LHRH Analogs – The Market Driver.....III-57
Current and Future Analysis.....III-57
Clinical Trials.....III-57
1$75
   Product Launch.....III-58
Strategic Corporate Developments.....III-58
2$150
   Select Players.....III-602$150
   B. Market Analytics.....III-62
Table 43: UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-62
1$200
  2e. Spain.....III-632 $200  
   A. Market Analysis.....III-63
Overview.....III-63
Spanish Prostate Cancer Therapeutics Market – On a Roll.....III-63
Current and Future Analysis.....III-63
Strategic Corporate Developments.....III-63
1$75
   B. Market Analytics.....III-64
Table 44: Spanish Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-64
1$200
  2f. Rest of Europe.....III-653 $225  
   A. Market Analysis.....III-65
Current and Future Analysis.....III-65
Clinical Trials.....III-65
Strategic Corporate Development.....III-65
1$75
   Select Players.....III-661$75
   B. Market Analytics.....III-67
Table 45: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-67
1$200
  3. Rest of World.....III-6812 $1100  
   A. Market Analysis.....III-68
Current and Future Analysis.....III-68
A Peek into Canadian Market.....III-68
Table 46: New Cases of Prostate Cancer Diagnosed in Canada (2008): Breakdown by Leading Province (includes corresponding Graph/Chart).....III-68

Table 47: Mortality Due to Prostate Cancer Diagnosed in Canada (2008): Breakdown by Leading Province (includes corresponding Graph/Chart).....III-68
1$200
   Table 48: Prostate Cancer Market in Canada (2008): New Cases and Deaths Due to Prostate Cancer by Age Group.....III-69
Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate
  Cancer.....III-69
Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy.....III-69
1$200
   Select Canadian Players.....III-701$75
   A Glance into Other Select Markets.....III-71
Minimally Invasive Devices Likely to Get Good Reception in Emerging
  Markets.....III-71
1$75
   Cancer Market in Asia.....III-72
Australia.....III-72
India.....III-72
Japan.....III-72
1$75
   Malaysia.....III-73
Table 49: New Cases of Prostate Cancer Diagnosed in Asia-Pacific: Breakdown by Region/Country for the Years 2007 and 2008 (includes corresponding Graph/Chart).....III-73

Table 50: Mortality Due to Prostate Cancer in Asia-Pacific: Breakdown by Region/ Country for the Years 2007 and 2008 (includes corresponding Graph/Chart).....III-73
1$200
   Cancer Market in Latin America.....III-74
Brazil.....III-74
Mexico.....III-74
Argentina.....III-74
Table 51: New Cases of Prostate Cancer Diagnosed in Latin America: Breakdown by Region/Country for the Years 2007 and 2008 (includes corresponding Graph/Chart).....III-74
1$200
   Table 52: Mortality Due to Prostate Cancer in Latin America: Breakdown by Region/ Country for the Years 2007 and 2008 (includes corresponding Graph/Chart).....III-75
Clinical Trial.....III-75
Product Launch.....III-75
1$200
   Strategic Corporate Developments.....III-762$150
   Select Players.....III-781$75
   B. Market Analytics.....III-79
Table 53: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-79
1$200
IV. COMPETITIVE LANDSCAPE 536$995
  
Total Companies Profiled: 138 (including Divisions/Subsidiaries - 153)

Region/Country                 Players


The United States                99
Canada                           10
Japan                             4
Europe                           35
     France                       6  
     Germany                      3
     The United Kingdom          11
     Spain                        2 
     Rest of Europe              13
Asia-Pacific (Excluding Japan)    5
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign